Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (8250)	9/18/2000 12:36:25 AM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 9719

Re. E25 by TNOX/DNA/NVS: "Genentech and Novartis Submit Application for FDA Approval of Anti-IgE Antibody" genentech.com Don, to be best of my knowledge, Novartis has pulled out of some of the trials pending investigation of the monkey data with E26. However, I have not seen anything suggesting that Novartis has bailed out of the FDA filing (BLA) itself. Also, like BGEN's, the IDEC molecule targets CD40 ligand; maybe we should start using the official, CD154, designation to avoid further confusion: Humanized Anti-gp39 (IDEC-131). In December 1995, we entered into a research and development collaborative agreement with Eisai. The collaboration focuses on developing humanized and PRIMATIZED antibodies against the gp39 antigen. This antigen, also referred to as the CD40 ligand, is an essential immune system trigger for B-cell activation and antibody production. from the March 10K sec.gov IDEC-151 is an anti-CD4 (no zero), from the same 10K: PRIMATIZED Anti-CD4 (IDEC-151) (Clenoliximab)................... Rheumatoid Arthritis Phase II I've found the fact-checking in GEN consistently "lacking," to be polite. Then again, I get exactly what I pay for -g- PB